Free Download Joint Formulary Committee, "British National Formulary Ed 85"
English | ISBN: 0857114581 | 2023 | 1904 pages | PDF | 18 MB
The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by health professionals across the world to support confident decision-making at the point of care. The new edition (BNF 85) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines. Extensive content updates in the BNF 85 edition include: New monographs for: * Aklief® (trifarotene) for acne vulgaris * Drovelis® (drospirenone with estetrol) for hormonal contraception * Ducressa® (dexamethasone with levofloxacin) for prophylaxis or treatment of postoperative inflammation, or prevention of infection, following cataract surgery * Kerendia® (finerenone) for chronic kidney disease associated with type 2 diabetes * Magnesium citrate for treatment and prevention of magnesium deficiency * Netildex® (dexamethasone with netilmicin) for local treatment of eye inflammation and bacterial infection * Nettacin® (netilmicin) for local treatment of eye infection * Sibnayal® (potassium citrate with potassium bicarbonate) for distal renal tubular acidosis * Tenkasi® (oritavancin) for acute bacterial skin and skin structure infections * Vydura® (rimegepant) for treatment or prophylaxis of migraine * Xerava® (eravacycline) for complicated intra-abdominal infections MHRA advice on: * Anagrelide: risk of thrombosis, including cerebral infarction, if treatment discontinued abruptly * Denosumab (Prolia®): should not be used in patients under 18 years due to the risk of serious hypercalcaemia * Dexmedetomidine: clinical trial finds increased risk of mortality in intensive care unit patients aged 65 years or younger * Metformin hydrochloride: reduced vitamin B12 levels and new advice for monitoring patients at risk * Methylphenidate hydrochloride long-acting (modified-release) preparations: caution if switching between products due to differences in formulations * Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists * Rucaparib (Rubraca®): withdrawal of third-line treatment indication * Topiramate (Topamax®): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure Other significant changes include updated guidance on: * Antibacterials for the prevention of secondary cases of diphtheria, and addition of guidance for the prevention of intra-uterine infection in preterm prelabour rupture of membranes * Contraceptive interactions * Prescribing of drugs associated with dependence and withdrawal * COVID-19 vaccines * Management of depression * Diphtheria vaccine * Management of epilepsy * Management of gout * Post-exposure prophylaxis of herpesvirus infections * Hydrocortisone: addition of children’s dosing for adrenal crisis * Management of hypertension in patients with type 1 diabetes * Management of multiple sclerosis * Obstetrics: preterm labour * Tacrolimus: updated pregnancy, breast-feeding and monitoring advice * Type 1 diabetes: inclusion of continuous glucose monitoring in aims of treatment * Type 2 diabetes: use of non-insulin antidiabetic drugs * Valaciclovir: update to indication and doses in line with UK Health Security Agency recommendations on post-exposure prophylaxis for chickenpox and shingles Order your copy and get: * Up-to-date information on prescribing, dispensing, and administering medicines * Authoritative, independent guidance on best practice enabling you to select safe and effective medicines * Information you can trust for quality and reliability * Everything you need at your fingertips, all in one book
(more…)
